Skip to content
    SINT
    Earnings call· Jun 2026(Q2 FY26)

    Sintx Technologies Q2 FY26 earnings call SINT

    Aug 11, 2026 Source

    Executive summary

    Sintx Technologies Q2 FY26 — Strong Revenue Growth Driven by Product Sales and OEM Orders

    Sintx Technologies reported significant revenue growth in Q2 FY26, driven by strong product sales and new OEM contract manufacturing orders, marking a transition towards commercialization. The company is focusing on converting demand into recognized revenue, establishing a disciplined commercial foundation for its foot and ankle wedge system, and prudently managing its cost structure and liquidity. Despite strong top-line growth, the company continues to face liquidity risks and increased net losses, necessitating ongoing efforts to secure additional funding and align expenses with its revenue base.

    Highlights

    5

    • Total revenue increased 199% year-over-year to $452,000 in Q2 2026.

    • Product revenue surged 347% year-over-year to $447,000 in Q2 2026.

    • Gross profit increased 388% to $278,000, with gross margins improving to approximately 62% from 38% a year ago.

    • Received purchase orders from contract manufacturing customers with an aggregate value exceeding $3.2 million.

    • Recognized initial commercial revenue from the SINTX osteotomy foot and ankle wedge system.

    Concerns

    5

    • Net loss remained flat at $2.3 million in Q2 2026 compared to the prior year.

    • Net loss for the first six months of 2026 increased to $5.5 million from $4.6 million in the prior year period.

    • Cash and cash equivalents decreased to $3.6 million at June 30, 2026, from $4.1 million at December 31, 2025.

    • Net cash used in operating activities increased to $5.3 million for the first six months of 2026, up from $3.7 million in the prior year period.

    • The current cost structure is high relative to the company's revenue base.

    Guidance & targets

    2
    CategoryTargetConfidence
    Total Revenue
    $900,000 to $1.1 million
    high materiality
    Medium
    Total Revenue
    $1 million to $1.3 million
    high materiality
    Medium

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Product Revenue
    Driven primarily by increased sales in OEM industrial manufacturing business and early commercial sales of the SINTX osteotomy foot and ankle wedge system.
    		$447,000347%——
    Grant and Contract Revenue
    Decreased significantly compared to $51,000 in the prior year period.
    		$5,000-90.2%——

    Operational metrics

    18
    Gross profit
    $278,000388% increase YoY
    Q2 FY26

    Compared to $57,000 in Q2 2025. This is an enrichment of a GAAP line.

    Gross margin
    61.5%vs 37.7% YoY
    Q2 FY26

    Improved from 37.7% in Q2 2025. Management noted this can vary based on product mix, pricing, manufacturing efficiency, customer demand, and revenue mix.

    General and administrative expense
    $2.3 million64% increase YoY
    Q2 FY26

    Compared to $1.4 million in Q2 2025. Partially offset by lower board fees, non-employee compensation, and accounting fees.

    Sales and marketing expense
    $273,000increased YoY
    Q2 FY26

    Increased compared to the prior year, associated with the SINTX product portfolio launch activity.

    Total revenue growth
    6%YoY
    H1 FY26

    Total revenue for the first 6 months of 2026 increased 6% from the prior year period.

    Product revenue
    $747,00091% increase YoY
    H1 FY26

    Product revenue for the first 6 months of 2026 increased 91% to $747,000.

    Revenue growth (excluding divested business)
    102%YoY
    H1 FY26

    On a comparable basis, excluding revenue associated with the divested PAMT business, revenue increased approximately 102% compared with the first half of 2025.

    Cash and cash equivalents
    $3.6 millionvs $4.1 million at Dec 31, 2025
    as of Jun 30, 2026

    Balance at quarter end.

    Current assets
    $7 million
    as of Jun 30, 2026

    Balance at quarter end.

    Current liabilities
    $3 million
    as of Jun 30, 2026

    Balance at quarter end.

    Stockholders' equity
    $4.8 million
    as of Jun 30, 2026

    Balance at quarter end.

    Inventory
    $2.3 millionvs $1 million at year end
    as of Jun 30, 2026

    Increase reflects inventory purchases and production activity to support anticipated customer demand and commercialization.

    Net cash used in operating activities
    $5.3 millionvs $3.7 million in prior year period
    H1 FY26

    Increase reflected higher net loss and working capital investment, partially offset by increases in accounts payable and accrued liabilities and non-cash adjustments.

    Net cash used in investing activities
    $91,000
    H1 FY26

    Due to investments in property and equipment.

    Net cash provided by financing activities
    $4.8 million
    H1 FY26

    Included net proceeds from June private placement and at-the-market sales, partially offset by debt payments.

    At-the-market program sales
    $1.3 million
    as of Jun 2026

    Amount sold under its 2025 at-the-market program.

    At-the-market program remaining capacity
    $5.1 million
    as of Jun 2026

    Remaining capacity under the 2025 at-the-market program.

    R&D expense reallocation
    $700,000
    Q2 FY26

    Overhead costs reallocated from R&D to G&A due to changing operating focus. This means the reduction in reported R&D expense does not reflect an equivalent reduction in underlying technical activity.

    Industry KPIs

    7
    MetricValueDetails
    Pricing realized priceImproved
    New product launch rampSINTX osteotomy foot and ankle wedge system
    Procedure volume growth—
    FCF conversion leverage guidance—
    Segment franchise organic growth347%%
    Sales force commercial capacity build—
    Pivotal trial clinical evidence milestonesFDA 510(k) clearance

    Product announcements

    1
    ProductTypeDetails
    SINTX osteotomy foot and ankle wedge systemlaunch

    Deals & partnerships

    2
    Multiple existing contract manufacturing customersPurchase orders for technically demanding componentsExceeding $3.2 millionProduction and shipment activities continuing into 2027

    These purchase orders are for components used in applications requiring mechanical strength, thermal stability, wear and corrosion resistance, manufacturing consistency, and quality control.

    Chris Lyons (board member) and Southern MetricsEngagement to help coordinate and evaluate inbound strategic opportunities

    This engagement is for potential commercial partnerships, licensing relationships, and other business development initiatives. It does not imply any particular transaction is pending or will occur.

    Risks & headwinds

    5
    Liquidity riskOngoing

    Cash and cash equivalents were $3.6 million at June 30, 2026, compared with $4.1 million at December 31, 2025. Net cash used in operating activities was $5.3 million for H1 2026.

    Mitigation: June private placement, remaining ATM capacity ($5.1 million), Armor facility sublease, pricing improvements, divestiture of non-core operations, and seeking additional equity/debt financing.

    Uncertainty in revenue recognition for contract manufacturing ordersQ3 and Q4 FY26, continuing into 2027

    Purchase orders exceeding $3.2 million, but revenue recognition depends on production, shipment, and other customary conditions.

    Mitigation: Aligning production schedules, managing working capital, protecting quality and delivery, evaluating capacity and process efficiency.

    High cost structure relative to revenue baseNear-term

    General and administrative expense increased 64% to $2.3 million in Q2 2026.

    Mitigation: Management is evaluating staffing, outside services, facilities, project priorities, working capital, and other spending to align with value creation milestones.

    Working capital pressure from contract manufacturing ordersOngoing

    Inventory was $2.3 million at June 30, 2026, compared with $1 million at year end, reflecting inventory purchases and production activity.

    Mitigation: Balancing supplier support and customer delivery requirements with responsible cash management; disciplined growth that avoids excessive working capital pressure.

    Surgeon adoption and channel development for foot and ankle wedge systemOngoing

    Initial commercial revenue recognized, but timing and amount of future revenue depend on surgeon adoption, channel development, product availability, and other market factors.

    Mitigation: Establishing a disciplined commercial foundation, surgeon education, case support, evaluating capital-efficient routes to market (direct-to-surgeon, distributors, strategic relationships).

    What to watch in Q3 FY26

    4

    Contract manufacturing revenue conversion

    Q3 FY26 and Q4 FY26
    CurrentPurchase orders exceeding $3.2 million received, production started.
    TargetRecognized revenue within Q3 and Q4 FY26 guidance range ($0.9M-$1.1M for Q3, $1.0M-$1.3M for Q4).

    Why it matters

    Successful conversion of orders to revenue is crucial for demonstrating execution and achieving financial targets, validating the commercial foundation.

    Based on our current production schedules, customer requirements, and expectations regarding the timing of📎 shipments, we currently expect total revenue to be approximately $900,000 to $1.1 million in the third quarter and approximately $1 million to $1.3 million in the fourth quarter of 2026.

    2 min read6 chapters

    Detailed Narrative

    01

    Transition to Commercial Focus

    SINTX Technologies is actively transitioning from a development-focused company to a commercially oriented biomaterials and medical technology platform. This shift is evidenced by the significant increase in product revenue and the initial commercialization of its proprietary medical devices. The company emphasizes converting demand into recognized revenue, establishing repeatable commercialization efforts, and aligning its cost structure with business scale.

    02

    Contract Manufacturing Business Performance

    The OEM industrial manufacturing business served as a primary driver of product revenue growth in Q2 2026, reflecting improved customer demand and pricing. SINTX views this segment as a crucial commercial foundation, providing near-term revenue, customer validation, and manufacturing utilization. The company announced receiving purchase orders exceeding $3.2 million, with production and shipment activities expected to continue into 2027, highlighting the significant value relative to current revenue.

    03

    Proprietary Medical Portfolio: Foot and Ankle Wedge System

    The SINTX foot and ankle osteotomy wedge system, which received FDA 510(k) clearance in late 2025, is the company's lead commercial product. Initial commercial revenue was recognized in Q2 2026 following its first clinical use in March 2026. The company is focused on building adoption and increasing commercial activity through surgeon education, channel development, and capital-efficient market access models, rather than pursuing growth at any cost.

    04

    Silicon Nitride Platform Potential

    SINTX's silicon nitride platform offers a combination of valuable properties for musculoskeletal applications, including biocompatibility, bone affinity, and imaging compatibility. Beyond the wedge system, the platform has potential applications across orthopedics, spine, dental, and wound care, utilizing various formats like monolithic implants, powders, and coatings. The company is prioritizing programs based on time to revenue, capital requirements, and strategic value.

    05

    Strategic Focus and Partnerships

    The company's strategy includes converting contract manufacturing demand, building a credible commercial path for the foot and ankle wedge system, and advancing OEM licensing and strategic discussions. SINTX is exploring partnerships to gain market access, development funding, and manufacturing volume, and has engaged a board member's company to evaluate inbound strategic opportunities. This approach aims to leverage external capabilities rather than building every commercial function internally.

    06

    Cost Structure and Liquidity Management

    While sales and marketing expenses increased due to product launch activities, research and development expenses declined primarily due to overhead reallocation to general and administrative expenses. Management acknowledges that the current cost structure is high relative to its revenue base and is actively evaluating staffing, outside services, facilities, and project priorities to align spending. The company continues to seek additional funding through equity and/or debt financing to address underlying liquidity risks.

    AI-generated summary of the company’s earnings call. Not investment advice.